Nasopharyngeal Carcinoma (NPC) is a commonly diagnosed head and neck malignancy in Southeast Asia. It also occurs more frequently amongst males than females. Epstein-Barr virus is a known common cause of infectious mononucleosis. After recovering, the EBV remains latent within the patient’s body and patients become life-long carriers.
Studies have shown that Epstein Barr Virus (EBV) can result in cancerous nasopharynx cells, however this relationship is yet to be fully understood. EBV is one of the many contributing factors of NPC, which also includes genetics, dietary and other environmental factors.
NPC-REAAD™ is an in-vitro diagnostic intended for qualitative and semi-qualitative detection of IgA antibodies in human serum samples for nasopharyngeal carcinoma.
It uses proprietary proteins developed by Restalyst to identify specific IGA antibody to EA seromarker segment.
Detection of EA is associated with higher specificity in comparison to other EBV related markers, resulting in fewer false positive during screening. This is particularly important and is a feature that our customers especially value with NPC-REAAD™. Fewer false positive results reduce unnecessary worry to patients and the requirement for them to undergo unnecessary procedures or treatments.
Gastric Carcinoma, also known as stomach cancer, has one of the highest incidence rate and mortalities worldwide, especially in Asia(Globocan,2012). The total estimated new cases in 2012 amounted to 952,000, which is approximately 6.8% of total new cancer cases (International Agency for Research for Cancer). There are no associated symptoms for early gastric carcinoma, most of the symptoms appear only at late stages. Late diagnosis is one of the main reasons that reduces effective treatments and increases complications to treat gastric carcinoma. Costly and invasive conventional methods for early screening and diagnosis such as endoscopy often deter people to seek early screening.
GC-REAADTM is an in-vitro diagnostic intended for early detection of gastric carcinoma using a patented biomarker. This biomarker was discovered to be expressed at high levels in the patient’s plasma samples. Additionally, risk factor for gastric cancer like Helicobacter pylori (H. pylori) infection, does not influence the biomarkers expression levels within plasma.
The competition between the patented biomarker and its specific antibodies is the gist of how GC-REAADTM functions. Positive or negative results obtained through calculations help to determine the patients’ status of gastric cancer.
Hepatocellular Carcinoma (HCC)is the most common type of liver cancer. Majority of HCC is a result of priori viral hepatitis infection (Hepatitis B or C), metabolic toxins such as ethyl alcohol or aflatoxin. It was once prevalent only in Southeast Asia and Afica due to intake of aflatoxin contaminated food grains. However, increasing alcohol consumption is the rising cause of hepatocellular carcinoma in Europe and America.
Disease symptoms are often discovered at late stages, preventing the possibility of early treatment and recovery. Patients with cirrhosis and hepatitis B infection have higher risk of developing HCC. Currently, the recognized screening test for HCC is using Alpha-fetoprotein (AFP) blood test and ultrasound exam (every 6 to 12 months).
Although AFP is widely used for HCC screening, patients with early stages of HCC can have normal AFP levels. The levels of AFP can be increased from other cancers.
HCC-REAADTM is an in-vitro diagnostic intended for early detection of hepatocellular carcinoma using a patented biomarker. Elevated levels of this biomarker were identified within hepatocellular carcinoma patients’ plasma. Internal research studies by Restalyst indicated that this patented biomarker produces better sensitivity than AFP.